SequelSEC

Coya Therapeutics, Inc. COYA

Pharmaceutical Preparations · CIK 0001835022 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$8.02M
Fiscal year ended 2026-06-30
Operating income
-$23.15M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$89.42MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.81Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue11.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth123.6%85th
Current ratio8.50x75th
SBC / revenue54.0%62th
Net margin-267.1%45th
Operating margin-283.9%47th

Coya Therapeutics, Inc. (COYA) reported revenue of $8.02M and net income of -$21.67M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Coya Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Coya Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$8.02M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$23.15M
Net income-$21.67M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$11.86M
Selling & marketingUnavailable

Balance

Coya Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$43.18M
Total assets$47.31M
Current assets$47.06M
Total liabilities$4.03M
Current liabilities$3.51M
Total equity incl. NCI$43.28M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.09M

Cash flow

Coya Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$15.72M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$31.20M
Net change in cashUnavailable
Stock-based compensation$5.31M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Coya Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-288.7%
FCF marginUnavailable
SBC / revenue66.3%
Current ratio13.40x
Revenue YoY growth1793.8%
Net margin-270.2%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open COYA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.